{
    "title": "A bill to promote the production of molybdenum-99 in the United States for medical isotope production, and to condition and phase out the export of highly enriched uranium for the production of medical isotopes.",
    "content": "approving the \n        temporary suspension of the restriction of export licenses.\n    ``g. As used in this section--\n            ``(1) the term `alternative nuclear reactor fuel or target' \n        means a nuclear reactor fuel or target which is enriched to \n        less than 20 percent in the isotope U-235;\n            ``(2) the term `highly enriched uranium' means uranium \n        enriched to 20 percent or more in the isotope U-235;\n            ``(3) a fuel or target `can be used' in a nuclear research \n        or test reactor if--\n                    ``(A) the fuel or target has been qualified by the \n                Reduced Enrichment Research and Test Reactor Program of \n                the Department of Energy; and\n                    ``(B) use of the fuel or target will permit the \n                large majority of ongoing and planned experiments and \n                medical isotope production to be conducted in the \n                reactor without a large percentage increase in the \n                total cost of operating the reactor; and\n            ``(4) the term `medical isotope' includes molybdenum-99, \n        iodine-131, xenon-133, and other radioactive materials used to \n        produce a radiopharmaceutical for diagnostic or therapeutic \n        procedures or for research and development.''.\n\nSEC. 5. REPORT ON DISPOSITION OF EXPORTS.\n\n    Not later than 1 year after the date of the enactment of this Act, \nthe Chairman of the Nuclear Regulatory Commission, after consulting \nwith other relevant agencies, shall submit to the Congress a report \ndetailing the current disposition of previous United States exports of \nhighly enriched uranium used as fuel or targets in a nuclear research \nor test reactor, including--\n            (1) their location;\n            (2) whether they are irradiated;\n            (3) whether they have been used for the purpose stated in \n        their export license;\n            (4) whether they have been used for an alternative purpose \n        and, if so, whether such alternative purpose has been \n        explicitly approved by the Commission;\n            (5) the year of export, and reimportation, if applicable;\n            (6) their current physical and chemical forms; and\n            (7) whether they are being stored in a manner which \n        adequately protects against theft and unauthorized access.\n\nSEC. 6. DOMESTIC MEDICAL ISOTOPE PRODUCTION.\n\n    (a) In General.--Chapter 10 of the Atomic Energy Act of 1954 (42 \nU.S.C. 2131 et seq.) is amended by adding at the end the following:\n    ``Sec. 112. Domestic Medical Isotope Production.--\n    ``a. The Commission may issue a license, or grant an amendment to \nan existing license, for the use in the United States of highly \nenriched uranium as a target for medical isotope production in a \nnuclear reactor, only if, in addition to any other requirement of this \nAct--\n            ``(1) the Commission determines that--\n                    ``(A) there is no alternative medical isotope \n                production target, enriched in the isotope U-235 to \n                less than 20 percent, that can be used in that reactor; \n                and\n                    ``(B) the proposed recipient of the medical isotope \n                production target has provided assurances that, \n                whenever an alternative medical isotope production \n                target can be used in that reactor, it will use that \n                alternative in lieu of highly enriched uranium; and\n            ``(2) the Secretary of Energy has certified that the United \n        States Government is actively supporting the development of an \n        alternative medical isotope production target that can be used \n        in that reactor.\n    ``b. As used in this section--\n            ``(1) the term `alternative medical isotope production \n        target' means a nuclear reactor target which is enriched to \n        less than 20 percent of the isotope U-235;\n            ``(2) a target `can be used' in a nuclear research or test \n        reactor if--\n                    ``(A) the target has been qualified by the Reduced \n                Enrichment Research and Test Reactor Program of the \n                Department of Energy; and\n                    ``(B) use of the target will permit the large \n                majority of ongoing and planned experiments and medical \n                isotope production to be conducted in the reactor \n                without a large percentage increase in the total cost \n                of operating the reactor;\n            ``(3) the term `highly enriched uranium' means uranium \n        enriched to 20 percent or more in the isotope U-235; and\n            ``(4) the term `medical isotope' includes molybdenum-99, \n        iodine-131, xenon-133, and other radioactive materials used to \n        produce a radiopharmaceutical for diagnostic or therapeutic \n        procedures or for research and development.''.\n    (b) Table of Contents.--The table of contents for the Atomic Energy \nAct of 1954 is amended by inserting the following new item at the end \nof the items relating to chapter 10 of title I:\n\n``Sec. 112. Domestic medical isotope production.''.\n\nSEC. 7. ANNUAL DEPARTMENT REPORTS.\n\n    (a) In General.--Not later than 1 year after the date of enactment \nof this Act, and annually thereafter for 5 years, the Secretary shall \nreport to Congress on Department actions to support the production in \nthe United States, without the use of highly enriched uranium, of \nmolybdenum-99 for medical uses.\n    (b) Contents.--The reports shall include the following:\n            (1) For medical isotope development projects--\n                    (A) the names of any recipients of Department \n                support under section 3;\n                    (B) the amount of Department funding committed to \n                each project;\n                    (C) the milestones expected to be reached for each \n                project during the year for which support is provided;\n                    (D) how each project is expected to support the \n                increased production of molybdenum-99 for medical uses;\n                    (E) the findings of the evaluation of projects \n                under section 3(a)(2); and\n                    (F) the ultimate use of any Department funds used \n                to support projects under section 3.\n            (2) A description of actions taken in the previous year by \n        the Secretary to ensure the safe disposition of spent nuclear \n        fuel and radioactive waste for which the Department is \n        responsible under section 3(c).\n\nSEC. 8. NATIONAL ACADEMY OF SCIENCES REPORT.\n\n    (a) In General.--The Secretary shall enter into an arrangement with \nthe National Academy of Sciences to conduct a study of the state of \nmolybdenum-99 production and utilization, to be provided to Congress \nnot later than 5 years after the date of enactment of this Act.\n    (b) Contents.--The report shall include the following:\n            (1) For molybdenum-99 production--\n                    (A) a list of all facilities in the world producing \n                molybdenum-99 for medical uses, including an indication \n                of whether these facilities use highly enriched uranium \n                in any way;\n                    (B) a review of international production of \n                molybdenum-99 over the previous 5 years, including--\n                            (i) whether any new production was brought \n                        online;\n                            (ii) whether any facilities halted \n                        production unexpectedly; and\n                            (iii) whether any facilities used for \n                        production were decommissioned or otherwise \n                        permanently removed from service; and\n                    (C) an assessment of progress made in the previous \n                5 years toward establishing domestic production of \n                molybdenum-99 for medical uses, including the extent to \n                which other medical isotopes that have been produced \n                with molybdenum-99, such as iodine-131 and xenon-133, \n                are being used for medical purposes.\n            (2) An assessment of the progress made by the Department \n        and others to eliminate all worldwide use of highly enriched \n        uranium in reactor fuel, reactor targets, and medical isotope \n        production facilities.\n\nSEC. 9. REPEAL.\n\n    The Nuclear Safety Research, Development, and Demonstration Act of \n1980 (42 U.S.C. 9701 et seq.) is repealed.\n\nSEC. 10. BUDGETARY EFFECTS.\n\n    The budgetary effects of this Act, for the purpose of complying \nwith the Statutory Pay-As-You-Go-Act of 2010, shall be determined by \nreference to the latest statement titled ``Budgetary Effects of PAYGO \nLegislation'' for this Act, submitted for printing in the Congressional \nRecord by the Chairman of the Senate Budget Committee, provided that \nsuch statement has been submitted prior to the vote on passage.\n\n            Passed the Senate November 17, 2011.\n\n            Attest:\n\n                                                NANCY ERICKSON,\n\n                                                             Secretary."
}